Investing Billions - E11: Neil Datta, The Forbes Family Trust’s Approach to VC | Is there Alpha in Due Diligence? How to Signal Strength in Fundraising, and Should LPs be Fee Sensitive?
Episode Date: September 26, 2023David Weisburd sits down with Neil Datta, Managing Director of Optima Asset Management managing the wealth of some of the world’s most important people (including the late Queen Elizabeth II). We're... proudly sponsored by AngelList, visit https://www.angellist.com/tlp if you’re ready to level up your startup or fund. RECOMMENDED PODCAST: Every week investor and writer of the popular newsletter The Diff, Byrne Hobart, and co-host Erik Torenberg discuss today’s major inflection points in technology, business, and markets – and help listeners build a diversified portfolio of trends and ideas for the future. Subscribe to “The Riff” with Byrne Hobart and Erik Torenberg: https://link.chtbl.com/theriff The Limited Partner podcast is part of the Turpentine podcast network. Learn more: www.turpentine.co -- X / Twitter: @NeilDatta18 @dweisburd (David) @eriktorenberg (Erik) -- LINKS: Optima https://www.optima.com/ -- SPONSOR: AngelList The Limited Partner Podcast is proudly sponsored by AngelList. If you’re in private markets, you’ll love AngelList’s new suite of software products. For private companies, thousands of startups from $4M to $4B in valuation have switched to AngelList for cap table management. It’s a modern, intelligent, equity management platform that offers equity issuance, employee stock plan management, 409A valuations, and more. If you’re a founder or investor, you’ll know AngelList builds software that powers the startup economy. If you’re ready to level-up your startup or fund with AngelList, visit https://www.angellist.com/tlp to get started. -- Questions or topics you want us to discuss on The Limited Partner podcast? Email us at LPShow@turpentine.co -- TIMESTAMPS: (00:00) Episode Preview (01:43) Neil’s diverse background (03:00) Why is Optima a management company? (04:47) Why Neil is VC-skeptic (06:35) Diligence and hype (08:09) Institutional diligence on VC (12:00) Which stage to invest into venture capital? (13:15) Portfolio construction for an institutional endowment (16:06) Sponsor: AngelList (17:30) Diversification (18:40) Correlation and lesson from the last crisis (20:40) Diversification within different stages? (21:45) Bullish on healthcare (25:20) LP Advice for Emerging Managers (28:55) Are top LPs comfortable with losing money in the correct way (30:35) Balancing reputation with diligence (32:00) The new SEC guidelines (33:35) Investors complaining about fund expenses (36:00) Fees and carry in VC (37:10) Optima's Star program
Transcript
Discussion (0)
I have this running joke in the office that the best way to raise money is to tell people
you're not taking money.
It works, right?
Like when you're aggressively fundraising and there's a certain FOMO aspect to a manager
where you know that they're going to be oversubscribed and you may not get capacity, there's power
in that.
As an LP, these types of conversations sometimes are easy, but sometimes they're not,
right? You want to understand, hey, you know, give me an example of something that didn't work out
or a losing trade. And you want to understand, you know, kind of a postmortem perspective,
you know, what they did wrong, what they learned from. Maybe more importantly than money lost is
you want to understand the thought process. You want to understand what they did then and potentially
how they would do something differently. Because one thing that's been drilled into me for the last
20 years is that past performance is not indicative of future results. And while that's true,
it does de-risk the investment. Neil Dada, Managing Director, Optima Asset Management. You've had a very unique background
ranging from working on the public sector, tracking down financial crimes to today working
as part of the team that managed the private fortune of the late Queen Elizabeth II.
Welcome to Limited Partner Podcast. Thanks for having me.
So tell me how you went through this diverse background of working in the public sector
to managing the wealth of some of the most important people on the planet.
Yeah. So I've been an institutional investor for 15 years. I've been lucky enough to work
with some of the smartest, most impressive, best performing investment managers in the world.
Really, my team is responsible for sourcing investment opportunities for the folks we
manage capital for. As you noticed, it's a high profile, impressive group. So that keeps us on
our toes. And really, my job is to diligence opportunities and de-risk them as much as
possible, such that they fit into our mandate and they have appropriate
kind of controls in place and have kind of all the institutional best practice that we expect
from our managers. You're head of risk and operational due diligence at Optima. Tell me
what you do on a daily basis and explain the alpha or potentially the loss aversion that you're able
to capture by doing the right diligence and doing
the right risk assessment on your investments? My job is to vet every opportunity that comes
through our door. We apply a rigorous review that includes document review, on-site meetings,
speaking to both the investment team as well as the operational team.
We take the view that it's almost like a mini SAS 70 assessment. And I think that gives us a good holistic view
of not just the investment opportunity, but the management company as a business,
because we typically make long-term investments. So it's really important to us that the management
company is well-situated and in a position to continue to provide alpha for us as
LPs. And when you say you look at it not just as a fund as a management company, what do you mean by
that? We assess not just their investment strategy, but the folks that are running the business,
what software they use, what their investment process is like. We have the benefit of seeing
most well-known institutional investors. So we
kind of from our seat, we could see what's best in class, what folks are doing in terms of process,
in terms of software, in terms of, you know, folks that are on the team. And it's like thinking
about Alpha, it's super unique because we're in the position to add Alpha as LPs. This is
something that I do often and really enjoy, because usually it's
emerging and startup managers who, you know, are looking to bring in institutional capital,
and just kind of curious what we look for, what type of systems we prefer, what type of reporting
do we prefer. And from that perspective, we're able to kind of bring them up the curve and make
them kind of more appropriate for institutional allocation. And it becomes kind of a win-win from an investment standpoint to
be able to add value. And generally, these managers appreciate it. So it tends to
build some goodwill and allows to be long-term partners with these folks.
One thing in 2011, between my first and second year in business school, I interned at a hedge
fund of sorts. And
I got to meet with a lot of emerging with these hedge fund hotels. One of the things that really
stuck to me is that if you want to be a $500 million, billion dollar hedge fund, you have
to start working and acting as if you're that level at the early stage. So really, it's kind
of a chicken egg. But the way you solve that chicken egg is by starting to act
institutionally early on. We get criticized, me and Eric, that we only bring on very,
very bullish VC people. You're our first kind of VC skeptic. What makes you skeptical about
venture capital today? I am bullish on venture as an asset class and generally as an opportunity
set. I think as an investor that looks at both public and
private markets, and you alluded to this just now, that the observation that I've seen personally
is that it's gotten much easier to launch a venture fund over the last few years.
At the same time, it's gotten much harder, much more expensive to launch a public equity fund.
Regulation, compliance requirements, reporting. The byproduct of that
is that there are a lot of recent entrants into venture who may not necessarily be in the best
position to generate alpha. Our job is to really handicap those opportunities and put us in the
best position and take the best horses in the race to build portfolios for our clients.
Before we went live, you mentioned in passing that some venture funds with a billion dollars
under assets have worse infrastructure than some much smaller hedge funds. What did you mean by
that? Venture capital, unlike hedge funds, it's an illiquid asset class, right? So when you're
thinking about public market investing, hedge funds and mutual funds,
there's generally some goalposts that managers have to pass, things like audits and regulatory
reviews, investor diligence sessions. Sometimes you find that venture capital managers,
particularly those with size, have gotten to a certain size of AUM and haven't had to go through those growing pains.
And a lot of times, they're kind of doing some of this stuff that early stage hedge
funds had to do a while ago.
And I think that's part of the diligence conversation.
And that's why diligence is so important.
I think it's really interesting.
If you think about the decade between the great financial crisis and the pandemic, by
any metric you choose, whether it's number of deals, size of rounds, new funds launched,
venture capital has exploded.
And social media has given these folks reach that was previously impossible.
But I think that definitely created some FOMO.
And folks in my position, that's something we have to deal with and really separate the hype
from what's real. So yes, I mean, I've seen cases of large AUM VC shops that don't produce
independent NAVs that have really kind of suspicious expense policies, obvious conflicts
of interest, or just maybe aren't comfortable being scrutinized.
And that, quite honestly, is something that's super rare when it comes to public market investing.
So maybe stemming from the fact that having a redemption window kind of forces you to
be on the right side of best practice.
That's where diligence comes in.
And that's how you separate the institutional, well-managed shops from the folks that maybe had a win early on and are resting their laurels.
That's an interesting point. The 10-year fund period in VC leads to different incentives than a hedge fund where you typically have a gate in a year and you could reconsider.
It also makes it easier to start to gather the first check into a hedge fund or to get somebody to commit for the first time, but harder to retain them. So there's definitely some trade-offs there.
When you do, quote unquote, institutional diligence on VCs, what are you looking for?
It's not that different. What we look for many, investment manager. We look for an edge. We look
for the ability to generate alpha that is somewhat repeatable. We look for institutional infrastructure that is commensurate with best practice. And to be clear, that means different
things for different strategies. There's a certain expectation we have for a billion-dollar equity
manager versus a venture capital manager. And coming from our seat, from seeing all sizes and
iterations of these managers over
kind of the 30-year history of Optima, we're kind of in the best position to
diligence these opportunities.
We could say with authority, hey, you're doing this, maybe you should do this a little bit
differently, or maybe have you thought about this in terms of research process?
Or going back to our earlier point, investors appreciate that we are LPs that can add value. If you view these as partnerships,
then it ends up being a win-win for both parties.
We interviewed the co-founder of Tribe, Jonathan Su, and for every portfolio company,
they provide a report. And even though they end up passing on the majority,
large majority of companies, they're able to produce something of value.
I think there's a positive selection there that people that want the feedback and that embrace it are going to be the ones that
are at the top, both entrepreneurs as well as fund managers. Despite your criticism of the
not enough diligence in the venture space, you're still are in some of the most storied franchises
in venture capital. What made you want to invest into these venture funds?
I think it's really easy to forget that venture capital is an asset class where the asset itself
has to approve every investor personally. If I want to buy Tesla, I got 300 bucks in a brokerage
account. There's not much Elon can do to stop that from happening. And that kind of aspect to it is a powerful motivating factor from a founder's
perspective. You know, big name managers, Sandhold Road firms tend to have institutional LPs,
they tend to have corporate relationships, they may have investors that are, you know, CEOs of
former portfolio companies, that aspect of access and flywheel that is really important in venture,
it's really tough for emerging startup managers to replicate that. From the deal flow perspective,
when I speak to smaller managers, they tend to focus on value add. They effectively are
proving to us why someone takes their money. But when you're one of the big guys in Sandhold Road,
they don't need to have that conversation. That ship's already sailed to a certain extent.
So for us, we need to understand, hey, which particular investment is going to add the most
value for us? And for somebody like myself, I don't need to focus on business risk. I don't
need to focus on going concern risk. I don't need to worry about whether or not they can pay their employees or keep the lights on and be in a position to be in business for fund five and
fund 10. So it does de-risk the investment for us to a certain extent. But I also think there's
definitely alpha there to be one of the bigger players in the space.
I was speaking to Beezer Clarkson from Sapphire off podcast in real life. That happens once in a while. And she mentioned that there's different strategies, different ways to go after venture. You could, of course, wait until an emerging manager goes to fund four, and there's only about a dozen or so of those kind of funds. Or you could try to whittle through those thousands of funds early on. Her argument was that you're going to be highly adversely selected if you
wait for the emerged funds and that by fund four, fund five, you already have the top managers.
And of course, you have these large bank platforms which remain unnamed that are putting people into
KKR fund 15. Obviously, that's another extreme as well. How do you look at that? Where's the
alpha from in terms of a vintage and a stage that you want to go into venture capital? This logic applies to any manager. There's this, you know,
kind of human nature conversation of, you know, would you rather invest with somebody who's kind
of young and hungry and hasn't made it? Or would you rather invest with somebody who's a little
bit older, who's got more resources, and potentially has had some wins under their belts. I think both have utility.
I tend to think that the younger, hungrier, more emerging folks have the strongest incentives
to make it work because they haven't had their big win yet.
But I think that also potentially leads to suboptimal risk management.
But at the same time, to the point earlier, there's this flywheel effect
that you get with kind of the storied franchises. Yeah, it reminds me, there was a study that found
that the best founders were actually serial entrepreneur founders that had not succeeded
in the first one. The one that had succeeded in the first one actually were not as hungry. So
a little bit of experience, but a little bit of hunger seems to be the right combination. You have different clients with different risk return profiles. But if you look
at a generic client, let's say the average client, let's just for simplicity's sake, let's say
you're managing money for an endowment. What would be your allocation across all asset classes? What
would be some rules of thumb in terms of what you would want your portfolio to look like?
As you'll appreciate that the conversation is really different based upon the kind of risk return guidelines and liquidity requirements for each investor.
But thinking from like a long term perspective, I think what we do is we typically build portfolios
that are diverse and have exposure to the areas that we think are not just performing well today,
but set to perform well 5 to 10 years out. So we think of areas like technology, healthcare,
obviously mixing both public and private, but focusing on liquidity.
From an asset class perspective, it would be a mix of both traditional mutual funds,
but also alternatives.
We tend to have a kind of a strong bias towards alternatives, kind of given our history and DNA
as a firm. Usually that's going to be in the form of a mix of hedge funds, private venture,
and more traditional asset classes like fixed income and public equity.
What does venture capital as an asset class compete against?
What is its nearest comparable? I would put venture in the alts bucket. The challenge in
kind of wealth management universe is that, you know, typically that sleeve may be 10% or less.
So you're competing against hedge funds and CTAs and private equity for a piece of the pie,
which is significantly smaller than what they do for fixed income.
That model may not be the best way to look at it.
I mean, that model really relies on kind of the old school 60-40 asset allocation model,
which we generally don't believe in.
One thing that I'm a proponent of is that diversification protects wealth where concentration
builds wealth.
You know, that's kind of a view that we've had for a long time.
And we've had the benefit, you know,
at Optima of allocating for best performing equity managers over the last 30 years.
And we've done a lot of analysis around this.
And it's really interesting when you kind of back out their performance
and you look at kind of the factors that drive it.
And a lot of times you find
that the highest conviction names at a manager are typically the, you know, number one, number two,
the top five positions. And usually, you know, if you're using kind of hindsight as a proxy,
you find that the highest conviction names tend to perform better than the actual
performance of the portfolio. So it kind of solidifies what our thinking is that you want
to do your homework, but you want to make concentrated bets with specialists to be in
a position to best monetize macro events, whether they're in a specific sector or a specific asset class.
Hey, we'll continue our interview in a moment after a word from our sponsors.
The Limited Partner Podcast is proudly sponsored by AngelList. If you're a founder investor,
you'll know AngelList builds software that powers the startup economy. AngelList has recently rolled
out a suite of new software products for venture capital and private equity that are truly game
changing. They digitize and automate all the manual processes that you struggle with in traditional fundraising and
operating workflows, while providing real-time insights for funds at any stage, connecting
seamlessly with any back-office provider. If you're in private markets, you'll love AngelList's new
suite of software products. And for private companies, thousands of startups from $4 million
to $4 billion in valuation have switched to AngelList for cap table management. It's a modern, intelligent equity management platform that
offers equity issuance, employee stock management, 409A valuations, and more. I've been a happy
investor in AngelList for many years, and I'm so excited to have them as a presenting sponsor.
So if you're ready to level up your startup or fund with AngelList, visit www.angelist.com slash TLP. That's AngelList
slash TLP to get started. Back to the show. Yeah, we found that to be the case. Check size
is the highest predictor of conviction, which is the highest predictor of return. And I think
there's a misnomer in venture capital in general that everybody's spraying and praying. No one
knows who's going to be good. I think it's very clear. If you look at some of the most competitive rounds in history,
it was Google Series A and Facebook seed round. That is not a coincidence. It's statistically
one in a million chance that that would just happen to be a random. You mentioned diversification.
What are ways to quantify diversification? What is a diversified portfolio? What is a
not diversified portfolio? So I guess looking at equity land, typically, what we would think of kind of a diversified
portfolio would be, you know, call it 30 or less positions. Think of it as, you know, the kind of
the top five positions are 30-ish percent or 20-ish percent of the portfolio. And in terms of
equity funds, that's fairly concentrated. You know. When you think of venture, that's a little bit of a different conversation. But one thing I find as an LP
is that a lot of venture managers don't think about portfolio construction or macro in a thoughtful
way. And that's something that we think about as global investors. So it's really our job to kind of put a macro overlay and make sure our
clients have appropriate exposure from a liquidity perspective. It's one difficult thing to handicap.
In terms of correlation, that's always been kind of the uncorrelated asset that's been the golden
grail. And then we saw in the last market cycle, somehow crypto is totally correlated with growth stocks,
which is correlated with anything riskiness. How do you look at correlation diversification
moving forward from the learnings from the last crisis? And from a risk perspective,
we look at correlation, both correlation to benchmarks, correlation to indices,
correlation to kind of their peers. That's something we look at quite closely.
And also diversification from a liquidity standpoint in terms of an asset liability
mismatch, but also from a top-down perspective, right? And from a correlation perspective,
if I have a portfolio that has 20 positions and two of those positions have greater than 85% correlation to
each other, I got to ask myself, do I need both of them? I would prefer to have less relationships
and have better relationships than have a bunch of repetitive allocations where managers are
providing me similar or like exposure. So really, I think from an LP's perspective, our job is to make sure we
have kind of the best horses in the race, but also be in a position where you could have a buy list,
but not allocate to everyone, right? So you got to have a kind of a good roster of folks that are
on your bench, where there may be opportunities, whether it's a macro
opportunity or a specific geo or sector where you believe in it, but you just don't believe in it
right now. And I think it's important for us to have a really deep bench of next-up managers that
may not make sense now, but would when kind of the macro environment changes.
And just at a high level, venture capital as an asset class has ballooned significantly and
gotten larger and larger to the degree where I think you would say that pre-seed is completely
different than late stage. Are they the same asset class? Do you want to have some kind of
diversification within the
different stages? How do you look at that as a whole? I think it's really important to have
diversification because we can see a scenario where you invest in an early stage manager that
just focuses on tech, and then NASDAQ sells off and impacts everything. I put them all kind of
in the illiquid bucket. So I don't necessarily differentiate a manager
that writes safes or seed investments versus somebody who's series A or series B. Yes,
there's a different risk return expectation, but from an asset allocation standpoint,
they're still 10-year allocations. So I kind of think of them similarly,
but have different expectations based upon their strategy. You mentioned having a deep bench for your managers and kind of next
one up. What do you look for in your bench? And what are you looking for in the next generation
of managers in the venture capital space? One area that, not just venture capital,
but as a sector is healthcare, something we're really, really bullish on. And I think there's a lot of alpha there. One thing that I think is really, really interesting is that if you look at the technicals of the industry, if you compare the S&P two-year performance to the XBI over the last rolling 12 months, rolling five years.
Rolling two years, the S&P is flat. Rolling two years, the XBI is down over 40, which is a huge,
huge delta if you just back out the biotech stocks from the S&P.
So in our view, from a technical perspective, that sector of the market has sold off more aggressively
and sooner than the broader market.
And from an opportunity standpoint, that's what I'm really excited about.
And I think one thing that's interesting is that, you know, people tend to think of technology
as being synonymous for like software or cloud competing, but technology is technology.
There's a lot of aspects to it. And particularly in biotech, the forefront of science breakthroughs, things like gene
editing and liquid biopsies. Think of weight loss drugs that we view potentially could have
a trillion-dollar market cap in the future. Those are some of the things we're really excited about.
And from an asset allocation standpoint, and just from the perspective of being able to
capture as much of the alpha as possible, we take the view that it's important to have
both venture, early stage, late stage, and public exposure in our kind of healthcare
sector, and make sure that we're in the best position to capitalize on
forward-looking trends. In terms of biotech venture, where are the opportunities set?
Where's the alpha in the market as you see it today? Where are you pointing your portfolio?
Yeah, we're really, really excited about the opportunities in healthcare. One thing I like
to talk about is kind of spatial biology was really interesting. It's a new kind of technology where they're using
kind of AI to physically map in the 3D way how these drugs interact, like not just cells, but
within the cell, how different parts of the cell are interacting. That's unlimited commercial
applications for something like that. Another kind of tidbit I'd like to mention is that,
you know, the human genome project
was approximately 20 years ago and cost approximately $3 billion. Now the cost to
map one genome has gone from hundreds of thousands of dollars to approximately $100. And, you know,
the commercial applications of that are really kind of tip of the iceberg in terms of what's next. I think that the space,
it's definitely had its challenges over the last year or two. But if you have the patience,
if you have an appropriate time horizon and appropriate risk tolerance, it's a really
impressive place to be. And actually, talking about venture capital and biotech, if you look
at the last five years, there were a lot of really early stage companies that maybe were pushed to go public earlier than
they should have. So it's created a really interesting dynamic where there's kind of a
lot of binary investment opportunities that I think is perfectly primed for active management.
VC's two favorite words are power laws. It's generally seen as in general
technology by the biotech, given the, as you mentioned, binary outcomes, and the massive TAMs,
we've taken a look at some biotech companies, they're $3 trillion TAM. And you say, that sounds
like a ludicrous number. And then you just do the math. And it's just a math equation. Let's move on
to advice for general partners. Specifically, we have a lot of emerging managers.
What are some points of advice that you would give emerging managers on how to better themselves?
Honestly, being kind of transparent is probably the best piece of advice I can give.
There's this kind of diligence aspect to they're trying to put on their best face and obviously win the business. And your job is to understand and really make sure that you have a good appreciation for
what's going on behind the covers.
And I think that from an LP's perspective, having these conversations over and over again,
you tend to hear a lot of the same things over and over again.
And some of these managers may be not as unique as they think they are. It's helpful from an LP
perspective to be able to say, hey, this is what we do. This is how we do it. Yes, we could do
these things differently from a best practice perspective, things like independent administrator,
independent valuation, auditors, having all these kind of controls in place that investors
appreciate. The other thing is the open to being scrutinized.
I think one big difference between typical kind of smaller venture manager and smaller
kind of public manager is that most public equity managers are expected to be scrutinized
and they welcome it to a certain extent, where I think the venture capital industry still
has to get over this lack of transparency.
And more recently, the private funds announcement from the SEC is going to go a long way towards that in terms of forcing folks to be a little bit more transparent about their fees, be
a little bit more transparent about their fair value portfolio holdings.
I think we're moving in the right direction.
But in terms of advice, I would say that realize that, you know,
obviously, they're vetting you, but ultimately, you know, it's a partnership and, you know,
we want you to succeed and it's in our best interest that, you know, you do the right thing.
So, you know, kind of view us as a resource and make it as non-contentious as possible.
Yeah, an odd thing happened in the last couple of years. One of my funds was oversubscribed.
I was basically vetting. I was trying to get the LP. I was telling them everything.
I took them through case studies of when I lost money. And of course, the LP was like,
how could I subscribe? And I could feel that it was this style of selling essentially
unintentionally that was very
effective, just the hyper-transparency.
How do you look at that?
I have this running joke in the office that the best way to raise money is to tell people
you're not taking money.
It works, right?
Like when you're aggressively fundraising and maybe desperate is not the right word,
but it does come off.
There's a certain FOMO aspect to
a manager where you know that they're going to be oversubscribed and you may not get capacity.
There's power in that. As an LP, these types of conversations sometimes are easy, but sometimes
they're not. You want to understand, hey, give me an example of something that didn't work out or a losing trade. And you want to understand, you know, kind of a post-mortem
perspective, you know, what they did wrong, what they learned from. Maybe more importantly than
money lost is you want to understand the thought process. You want to understand what they did
then and potentially how they would do something differently. Because one thing that's been drilled
into me for the last 20 years is that
past performance is not indicative of future results. And while that's true,
it does de-risk the investment somewhat.
Has it been in your experience that top LPs are comfortable with losing money in the correct way
where more mediocre LPs are really focused on downside protection versus really making sure you get good
returns in venture. I think that's fair. I do think that, you know, obviously sophisticated LPs
understand market dynamics a little bit better. You know, things like the last 18 months in venture
down rounds and what's been happening in the industry broadly, there may be a, you know,
high net worth or somebody who's less
exposed to the market who just expects an absolute return profile. But if you're not
in the weeds and not seeing what's going on in the broader market, you may miss that.
So I do think, going back to liquidity and capacity, it's an interesting conversation
because there have been multiple times where
I've spoken to managers who intentionally make their liquidity more onerous than it
needs to be.
For example, an equity manager who could do weekly liquidity but chooses to do semi-annual.
And it makes you wonder why.
And really, what they're doing is they're protecting the fund from their investors.
And there's obviously an aspect to that in venture. But in venture, you understand like, hey, you're putting
your money on a boat, you're pushing it out to sea, and you're hoping at some point the boat
comes back bigger. One of my favorite tweets in VC is VC is 99% saying no and 1% begging,
especially the case in the last bull market. And you saw rounds go from 60 days
to 60 hours in terms of closing. And it created this pressure that a lot of VCs don't want to
talk about, which is this pressure to be overly founder-friendly. I'm, of course, a two-time
founder myself. I value founder-friendliness probably more than most VCs, but you have to
say, I still have to do my diligence. How do you balance your reputation as an LP with your need to be diligent and to be a good fiduciary for your clients?
I mean, I would argue that my reputation as an LP is in my diligence. So the fact that they know
I'm going to be a pain in the ass is kind of the reputation I want, to be honest. And I think they
appreciate that. And just kind of as evidence of that, I've been asked to be
a reference for multiple head managers because when I speak to another LP and I say, hey,
I didn't love this. This is what they did. This is how they answer these questions. I try to
take a friendly approach as possible, but they recognize that we're not pushovers. We have the
benefit of having best-in-class terms almost everywhere we go. So that is
our expectation, generally speaking, for most relationships. And we're additive LPs and we do
believe that a relationship with us is going to add value to them as well.
And you're talking best in class in terms of MFN?
That's going to be a little bit more difficult going forward, right? MFNs are going to be a little bit challenged and not allowed going forward.
But I do think that there are certain things that institutional investors have grown accustomed
to, even not from an MFN perspective, but maybe in terms of access and relationships
and just kind of softer, more subtle type data points.
And you can make the argument that that's
really where kind of the nuance is, where the secret sauce is, like being able to
decipher and differentiate one investment versus another. That's where ultimately the 30 years of
experience of doing this as a firm, that is where I think ultimately the value is and what our
investors, our expectables. We have a lawyer coming on soon to unpack the new SEC guidelines. Have you had a chance to
take a look at them and any thoughts on how, without giving legal advice, how that might
change the industry at a high level?
We're clear, I'm not a lawyer and not in a position to comment legally, but just reviewing
the bullet points, it seems as though they backtracked on the big kind of negligence difference, which I think had a lot of people worried in terms of, you know, legal liability.
So that was probably a positive walkback.
The changes to kind of transparency and fees and, you know, kind of administrator standard, which, you know, I would argue everyone should be on an
administrator, but not every VC fund is. I think those are all positive. You know,
like the expense piece specifically is something that I, for years, I've had an issue with and
a lot of, you know, uncomfortable conversations that I've had with managers. So like the fact
that the US now is kind of, you know, on the right page and the Europeans have been a little bit
far ahead of this, I think it's a good thing for the industry.
You mentioned expenses. One LP told me that LPs love to gossip and complain, for lack of a better
word. But another funny thing that he told me is that a lot of LPs will complain about funds and
continue to invest because of the performance. What are your views on that? Do you have to take a dogmatic view and say, hey,
you know, this guy is expensing his private jet, even though he's returning 5x, I'm not going to
invest? How do you navigate that? And how do you kind of socialize this with your own clients?
It's an interesting conversation. And I've definitely some debates I've had around this.
And, you know, I think the kind of the best example is, you know, SAC, where they had in maybe one of the best track records that you've seen, but also a really onerous fee structure.
And I don't think any of their investors complained about it, right? Because net net,
they were better off.
It's something that I don't really think about a whole lot in terms of right and wrong aspect to it.
I think of it in terms of run rate, right?
So this is a manager's management fee, performance fee.
Here's a run rate.
So here's everything we're paying above that.
And is it commensurate with our expectations,
particularly with the asset class and the strategy, right?
So like, for example, your multi-managers, your millennials, 0.72s, citadels, they're
kind of in one bucket and they work a certain way.
But if a long-street equity or a venture manager had a fee structure similar to them, I'd have
an issue with that, right?
So I think this is where the experience comes in.
As an investor, you should be
mindful that some strategies are inherently more expensive to run. For example, activist strategies,
like your Bill Ackman's of the world who are taking public views against companies and proxy
battles. These are super expensive, like legal bills. So someone like that may have a massive legal bill that another firm wouldn't. So I think, yes, there's definitely a lot of shadiness, if you will, within expenses. And that's part of my job to managers may pass through that if they're annualizing
at 20 versus 10, they may have a little bit more leeway for it.
How much more stomachable are the quote-unquote fees when they're as carry? I had Samir Khaji
and Apoorva, and I just spoke to Michael at Sundana Capital, Michael Kim, and they state
that half to two-thirds of their
managers are doing kind of tiered carry structures over certain hurdles, like a 3X and a 5X.
How do you look at that in the venture capital space?
I do think terms are trending towards more investor-friendly, and they'll continue to do
that, particularly in this fundraising environment. Unless you're one of a handful of firms, you're facing fee pressure.
I think philosophically, the carry piece is more investor-friendly than the 2 and 20
traditional piece because you're not paying a fee and losing money, right? You've de-risked
that aspect to it such that you're only paying a carry after you've seen a profit.
And that is a little bit more difficult in other markets.
The way we think about it is, at the end of the day, it's a net cost, right?
So if you can stomach the fees and they're not doing anything crazy and it's kind of well within expectation of reasonableness, we deal with it.
Thank you for your transparency. And thank you for answering these hardball questions. I want
to give you a chance to share what you'd like our listeners to know about yourself, about Optima.
You're working on a lot of interesting projects. So anything you'd like our listeners to know about
Optima? Yeah, we mentioned the healthcare strategy. That's something we're really bullish on and can continue to do a lot of work on. The other thing that I think is interesting
to me specifically as an investor is that I think a few years ago, we launched the STAR program where
we kind of did some analysis and realized that if you think of investment managers, and particularly
like the best of the best,
the folks that have annualized at the highest numbers over the last 20 years, even those folks,
their alpha tends to be at the top of the portfolio, meaning the top three to five names.
So we ran an analysis where we backed out the performance of the top three to five names,
and compared that performance with the actual performance we received as
investors. And the numbers were quite compelling such that something like 75% of the time,
the track record that was the concentrated portfolio that was purely their best ideas
outperformed the actual commercial product that they were in market selling.
We took that analysis and built an algorithm around it. And we call it the STAR
program. And it was really interesting where we took our history of allocating to managers
and figured out who was good at what and built a portfolio around the best ideas of the best
folks in each space. That is something we launched and really bullish on and look forward to
continuing to expand that program.
Is the implicit assumption there is that every manager only has a few good ideas,
but is that essentially the assumption in the STAR program?
The assumption is that the folks that are in the best position in each individual strategy,
just by human nature, they're going to make their highest conviction ideas at the top of
their portfolio, right? Unlike venture where names grow against your will, you can size up and size down at will. If you have a position that's a 10% of
your portfolio, you better believe in it. The answer really is kind of top three to five names
are where the alpha is. If you look at statistics and a large data set, that's typically where it
is. So that's what we did. We backed out the top three to five names of really impressive track record hedge funds and built a 40 to 50
stock portfolio directly on those names. And that's effectively what it is. And I'm really,
really bullish on it. Thank you very much. We got to take a look at the venture world and the larger
asset management world through the
lens of risk and through somebody that's really had really rich experience across different asset
classes. So this is invaluable for myself and for the audience. Thank you for taking the time.
Thank you, David. Thanks for having me.
Thanks for listening to Limited Partner Podcast. If you like this conversation,
please like, subscribe, and review
on YouTube, Spotify, or Apple.
Thank you for your support.